By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Retrophin, Inc. 

3721 Valley Centre Drive
Suite 200
San Diego  California  92130  U.S.A.
Phone: 760-260-8600 Fax:


At Retrophin our mission is to deliver life-changing therapies to people living with rare diseases who have few, if any, treatment options. Giving patients a chance and providing hope is what drives us.

We are a fully integrated biopharmaceutical company focused on advancing the development of our lead pipeline assets: sparsentan for focal segmental glomerulosclerosis (FSGS), a kidney disorder that often leads to end-stage renal disease; and RE-024 for pantothenate kinase associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. These product candidates have pioneering potential, as sparsentan could be the first FDA-approved pharmacological treatment for FSGS, and RE-024 could be the first approved replacement therapy targeting the underlying cause of PKAN.

Our focus on R&D is supported by revenues from our commercial products: Thiola® – for patients with cystinuria; Cholbam® – the first and only FDA-approved treatment for people with bile acid synthesis disorders and Zellweger spectrum disorders; and Chenodal® – an FDA-approved synthetic bile acid that has been cited as medically necessary for the treatment of cerebrotendinous xanthomatosis (CTX), a progressive and underdiagnosed lipid storage disease affecting many parts of the body. Our Total Care HUB® eases patients’ access to these products by offering personalized and comprehensive support services – at no cost to patients, physicians or insurance companies.

Headquartered in San Diego with offices in Cambridge, MA and Dublin, Ireland, we have approximately 150 employees. Integrity, Accountability, Compassion, Teamwork, Scientific Excellence, and Entrepreneurial Spirit are the values that guide our work each day and what we expect from one another.


February 2011


CEO: Stephen Aselage

CFO: Laura Clague


Please click here for Retrophin job opportunities.


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Public

Web Site: Retrophin
Employees: 170
Symbol: RTRX


Company News
Retrophin (RTRX) Announces Cooperative Research And Development Agreement With NCATS And To Identify Potential Small Molecule Therapeutics For NGLY1 Deficiency 9/5/2017 10:38:46 AM
Retrophin (RTRX) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 8/15/2017 8:19:41 AM
Retrophin (RTRX) To Report Second Quarter 2017 Financial Results 7/27/2017 12:59:53 PM
Retrophin (RTRX) Commences Patient Dosing In International, Registrational Phase III Trial Of RE-024 In PKAN 7/25/2017 11:35:13 AM
Pharma Bro Martin Shkreli's Retrophin (RTRX) Fraud Trial Finally Starts Today 6/26/2017 5:55:39 AM
Retrophin (RTRX) Announces Expansion Of Intellectual Property Estate For Sparsentan With Newly Issued Patents In The United States And Europe 6/1/2017 10:32:32 AM
Retrophin (RTRX) Reports First Quarter 2017 Financial Results 5/5/2017 11:28:25 AM
Retrophin (RTRX) To Report First Quarter 2017 Financial Results 4/21/2017 8:52:17 AM
Retrophin (RTRX) Appoints Ron Squarer To Board Of Directors 4/13/2017 9:50:32 AM
John A. Orwin Joins Retrophin (RTRX) Board Of Directors 3/24/2017 8:35:35 AM